In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Actimis Pharmaceuticals Inc.

Latest From Actimis Pharmaceuticals Inc.

GSK Will Be A Limited Partner In Sanderling Ventures’ New Fund

The pharma pledges $50 million to the California firm’s new seventh round, which it anticipates closing more than eight years after its sixth. For GSK, it’s the latest tie-up with a VC firm as part of a regional investment strategy.

BioPharmaceutical Medical Device

Dealmaking When Pharma's the Only Game in Town

With no public market to provide competition, the theory among biotech's optimists was that Big Pharma would step in and buy lots of bargains. But cheap prices and easy availability haven't increased drug company appetites: They will only buy what they really want. Deal volumes, both for M&A and alliances, are falling, while Big Pharma has learned to put more of the risk back on biotech. What will change this dynamic, putting more bargaining into biotech hands, is the revival of the public market - and there are hints that such a revival may be on the way.
BioPharmaceutical Strategy

Start-Up Previews (12/05)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, The Double-edged Sword of Diabetes Drug Development, features profiles of Alba Therapeutics, Alinea, DiaKine and Diabetica. Plus these Start-Ups Across Health Care: Actimis, Luminous Medical, NABsys and Pathfinder Therapeutics.

Actimis Pharmaceuticals Inc.

Actimis Pharmaceuticals Inc. spun out from the research division of Bayer Healthcare AG with rights to five programs that represent a significant portion of the total Bayer small-molecule therapeutics portfolio for respiratory diseases. In the first quarter of 2006, the company hopes to move its first compound, a novel and potential breakthrough asthma treatment, into human trials.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Actimis Pharmaceuticals Inc.
  • Senior Management
  • Peter McWilliams, PhD, Pres. & Acting CEO
    Kevin B Bacon, PhD, CSO & Head, R&D
  • Contact Info
  • Actimis Pharmaceuticals Inc.
    Phone: (858) 458-1890
    10835 Road To The Cure
    Ste. 200
    San Diego, CA 92121